AU
UK
CA
NZ
IND
US
Ascentage Pharma announced regulatory clearances from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to initiate GLORA-4, a global Phase III registrational study of lisaftoclax in combination with azacitidine for first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS). The …
Evotec SE reported mixed first-half 2025 results, reflecting divergent trends across its businesses and a challenging discovery market. Group revenues declined 5% year over year to GBP371.2 million as Discovery & Preclinical Development (D&PD) revenue decreased 11% to GBP269.0 million, consistent with softer demand …
Shares of Cardinal Health, Inc. (NYSE: CAH) have received a consensus recommendation of “Moderate Buy” from fourteen research firms currently tracking the stock. Out of these, three analysts rate the stock as “Hold,” while eleven have issued “Buy” ratings.
RadNet, Inc. (NASDAQ: RDNT) reported its second-quarter 2025 financial results, posting record revenue and adjusted earnings. Total revenue for the quarter reached USD 498.2 million, an 8.4% increase from USD 459.8 million in Q2 2024. Adjusted EBITDA rose 12.3% to USD 81.2 million, with …
JPMorgan Chase & Co. has increased its price target for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from USD348.00 to USD475.00, according to a report released Wednesday. The firm maintained an “overweight” rating, indicating expectations for further gains from the company’s latest closing price of USD428.14.
Image source: © 2025 Krish Capital Pty.LtdHighlightsTruBridge posted Q2 2025 GAAP net income of USD 2.6 million versus a USD 4.4 million loss last year.Total revenue was USD 85.7 million, with recurring revenue comprising 95% of the total.Adjusted EBITDA rose to USD 13.7 million …
Baxter International Inc. (NYSE: BAX) has seen a wave of analyst activity following a series of price target revisions. Barclays recently cut its price target for the medical instruments supplier from USD 41.00 to USD 36.00, while maintaining an “overweight” rating on the stock. …
Mdxhealth (NASDAQ: MDXH) has reported its preliminary financial results for the second quarter and first half of fiscal year 2025, along with a strategic acquisition intended to accelerate its growth trajectory. For the quarter ended June 30, 2025, the company posted a 20% year-over-year …
Alcon (SIX/NYSE: ALC) and STAAR Surgical Company (NASDAQ: STAA) announced a definitive merger agreement under which Alcon will acquire STAAR in a transaction valued at approximately $1.5 billion. The deal, which includes the EVO Implantable Collamer® Lens (EVO ICL™) family, aims to expand Alcon’s …
Zepp Health Corporation (NYSE: ZEPP) announced unaudited financial results for the second quarter of 2025, marking its first year-over-year revenue growth since 2021. Total revenue came in at USD 59.4 million, representing a 46.2% increase over the same period in 2024 and a 54.2% …
Please wait processing your request...